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Antimicrobial resistance (AMR) is a threat to global health security and may reverse the gains in 
preventive medicine. This is worsened by the fact that development of resistance out-paces that of 
new antimicrobials. The factors driving the development of AMR range from health systems to 
socio-economic and environmental factors. These include poor antimicrobial stewardship, poor 
access to quality drugs, prescribing antimicrobials without susceptibility laboratory tests, use of 
antimicrobials in crop, animal production and aquaculture farming. Others are lack of coordinated 
medical and veterinary health systems strengthening, poor universal health coverage and practice 
of one health. The burden of the problem is of public health importance especially in Africa where 
there is high incidence of poverty, high incidence of out-of-pocket health expenditure, lack of basic 
social amenities and weak health systems with poor collaboration. The impact of AMR includes 
increased burden on the healthcare system, hospital admission, cost of patient treatment, poor clin-
ical outcomes and impact on food security, among others. In view of the interplay of various sys-
tems and factors in the development and emergence of AMR, there is need for multi-sectoral and 
interdisciplinary approach at global, regional, national and local levels for its prevention and mit-
igation. Strengthening of health systems from the medical and veterinary perspectives and univer-
sal health coverage are critical in the fight against AMR. The relevant stakeholders include politi-
cal leaders, community leaders, health professionals, academics, and research institutions, federal 
and state ministries of health, agriculture, education and Nongovernmental organisations among 
others.  
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Introduction 
The increasing health threat from emerging 
infectious diseases and Antimicrobial Re-
sistance (AMR) require an urgent global re-
sponse, especially in Africa for reasons such 
as weak medical and veterinary health sys-
tems (HS) and high poverty level, among oth-
ers. These could reduce access to appropriate, 
quality antimicrobials and subsequent emer-
gence of AMR. Antimicrobial resistance has 
been described as a global crisis by the 
United Nations (UN) General Assembly, 
World Health Organisation (WHO), world 
leaders of G7 and G20, World Bank (WB), 
African Union (AU) , European Union (EU); 
and it is one of the greatest threats to public 
health requiring urgent global response 
(1,2,3). It is a trans-boundary problem in 
which the organisms require no international 
passport (4). AMR threatens all countries in 
different ways and to varying extents; and de-
spite scanty information, the data available 
showed evidence of increasing trends of 
AMR in the African region and the rest of the 
world (5, 6). This paper discussed antimicro-
bial resistance, HS and universal health cov-
erage (UHC), their interactions and the po-
tential of applying the principle of universal 
health coverage to prevent/ mitigate the prob-
lem of AMR (Figure 1). 
Methods 
This paper is a narrative review using 
searches of peer-reviewed articles published 
between 1999 and 2020 in databases such as 
Pubmed, Medline, African Journal online 
(AJOL), Bioline international, Popline and 
google scholar; and grey literatures such as 
reports and research briefs. The words used 
for search were Africa, Antimicrobial re-
sistance, health systems and universal health 
coverage. 
Results and Discussion 
Antimicrobials and antimicrobial re-
sistance  
Antimicrobials are drugs used for the treat-
ment of infectious agents such as bacteria, vi-
ruses, fungi, parasites and have played prom-
inent role in human and veterinary medicine, 
agriculture and environment (7). They are 
global public good which have improved 
health care, saved lives and enhanced eco-
nomic gains (8, 9). Antimicrobials are cor-
nerstone on which the HS is standing on, not 
only for the basic treatment of infections, but 
also for medical and surgical procedures (10, 
11). However, the emergence of resistant mi-
croorganisms has compromised their effec-
tiveness (12). AMR is defined as the devel-
opment of resistance in a microorganism to 
an antimicrobial agent to which it was previ-
ously sensitive (13). Access to quality antibi-
otics which is a subset of antimicrobials used 
to treat bacteria is very essential in the treat-
ment and prevention of resistance. In Africa, 
AMR has been documented to be a problem 
for HIV and the pathogens that cause tuber-
culosis (TB), typhoid, meningitis, gonorrhea; 
Bovine TB, Pseudomonas oryzae and Pseu-
dononas syringae infections (1,14 ,15). Sixty 
percent of pathogens harmful to humans are 
of animal origin; humans and animals share 
the same bacteria (9). 
Drivers of antimicrobial resistance  
Many factors are contributing to the emer-
gence and spread` of AMR globally and in 
Africa. These include the overuse and misuse  
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of antimicrobials, sub-optimal infection con-
trol, use of antibiotics as massive depot prep-
aration in animal production with no observe 
of withdrawal periods, antimicrobial agents 
use for growth promotion in animal hus-
bandry, use of substandard and/ or counterfeit 
drugs in both medical and veterinary prac-
tices, poor capacity to conduct antimicrobial 
susceptibility testing, among others (1, 16, 
17, 18, 19). The transmission of AMR is ac-
celerated by impaired access to potable wa-
ter, limitations in public health prevention 
programs such as immunization and sanita-
tion (1). Vaccination of humans and animals 
is a very effective way to prevent them from 
becoming infected, thereby reducing the need 
for antibiotics for the infections that do not 
have existing vaccines (20). The develop-
ment of AMR and its spread to other organ-
isms via mobile genetic elements (plasmids 
and transposons) has been amplified by in-
dustrial discharges (pharmaceutical, agricul-
tural) and human wastes contaminating the 
environment (21).  In addition, antimicrobials 
are used to treat human, animal and plant dis-
eases, depending on the species treated and 
particular drug used, 10- 80% of the drug 
used is absorbed or metabolized, while the re-
mainder are excreted as active compounds 
through urine and faeces into the environ-
ment (21). Manure and waste water are used 
as fertilizers in farms and sub-therapeutic an-
timicrobials used for treatment can serve as 
selective forces in AMR emergence (21). An-
timicrobial resistant genes and bacteria with 
resistance to one or more drugs have been de-
tected in surface waters, in soils, in animal 
feeds and on edible plants globally (21).  
Food is likely to be quantitatively the most 
important potential transmission pathway 
from livestock to humans, although direct ev-
idence linking AMR in humans to food con-
sumption is lacking (22). The use of antibiot-
ics in chicken could cause resistance in hu-
mans; and MRSA in animals have been 
linked with that in humans (23, 24, 25, 26, 
27). The globalizations of trade in food prod-
ucts, conventional and medical tourisms fa-
cilitate the spread of resistant bacteria (9). So-
cioeconomic status has also been shown to 
have an influence on what antibiotic agents 
are prescribed and association with resistance 
and the linkages between poverty and AMR 
(28, 29, 30). Poor people are less likely to 
seek for medical prescription when indicated 
and may not afford complete treatment with 
adequate dose of antimicrobials (30). 
The burden of antimicrobial resistance  
The economic burden of AMR is difficult to 
calculate due to insufficient data and the need 
to account for externalities especially in Af-
rica (31). However, estimates of the impact 
of AMR on the US economy are exceedingly 
high, including $20 billion in direct health 
care costs with additional indirect costs as 
high as $25 billion, 2 million illnesses and 
23000 deaths per year(32). The WB projects 
that 24 million people could fall into extreme 
poverty by 2030 because of AMR and most 
would come from low and middle income 
countries. Globally, AMR is estimated to ac-
count for more than 700,000 deaths per year 
and if current trends continue, it will cost ap-
proximately 10 million lives per year and 
over US$100 trillion in lost output globally 
by 2050 (4). It has been estimated that about 
4,150,000 deaths will be attributed to AMR 
in Africa by 2050 (4, 13, 33).The increase in 
AMR could lead to a reduction in options 
available to treat infectious diseases, support 
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chemotherapy, surgery, and this will have a 
significant impact on the HS and economies 
(13). Infections with resistant organisms have 
been associated with increased hospital stay, 
increased morbidity and mortality, use of ad-
ditional drugs, laboratory tests and increased 
treatment cost (34, 35). This has financial im-
plications for the individuals, families, com-
munities and the HS (13). This has increased 
poverty as it has been documented that mil-
lions of Africans fall into poverty due to high 
out of pocket health payments (36). AMR 
could lead to loss of productivity from the 
spread of diseases to other animals and death 
of the animals, thereby threatening the sus-
tainability and security of food production 
and the livelihood of farmers. 
Drug related causes of AMR and health 
systems 
Poverty has been cited by WHO as a major 
force driving development of AMR (37). In 
developing countries factors such as inade-
quate access to effective drugs, unregulated 
dispensing and manufacture of antimicrobi-
als related to cost are contributory (37). 
While in America, poverty-driven practices 
such as medication-sharing, use of “leftover” 
antibiotics, the purchase and use of foreign-
made drugs of questionable quality are likely 
contributing to AMR; this has also been re-
ported in Africa (38). In many HS, wide-
spread inappropriate use of antibiotics com-
bined with inadequate access especially for 
the poor contributes to the problem of AMR 
(5). Poor collaboration between the human 
and veterinary/animal health sectors is also a 
problem. Little data exist about the individual 
practices of veterinarians in Africa and most 
antibiotic prescriptions are used during ani-
mal production. Veterinary antibiotics can be 
purchased on the open market just as human 
antibiotics and the lack of separation of anti-
biotics used for animals and that for humans, 
which have negative public health conse-
quences. Lack of stringent penalties on man-
ufacturing and distribution of substandard 
and counterfeit drugs in Africa is also a chal-
lenge (39).  
What has been done in response to AMR?  
The WHO 2015 Global Action Plan on AMR 
underscores the need for collaboration be-
tween human, animal, food and environmen-
tal sectors (7). Also, the WHO 2018 compe-
tency framework for health workers’ educa-
tion and training on AMR has four main 
AMR domains, namely building awareness 
of AMR, appropriate use of antimicrobials, 
infection prevention and control and diagnos-
tic stewardship (40). In Africa, the Africa 
Centre for Disease Control and Prevention 
(Africa CDC) has established the AMR Sur-
veillance Network (AMRSNET) which is a 
network of public health institutions and 
leaders from human and animal health sec-
tors who will collaborate to measure, prevent, 
and mitigate harms from resistant organisms. 
AMRSNET’s four goals are: improve sur-
veillance of AMR organisms among humans 
and animals; delay emergence of AMR; limit 
transmission of AMR and mitigate harm 
among patients infected with AMR organ-
isms (1). The Tripartite collaboration be-
tween WHO, Food and Agricultural Organi-
sation (FAO) and the World Organisation for 
Animal Health (OIE) has provided critical 
leadership to foster concerted efforts aimed at 
combating the threat of AMR at a global level 
in recent years but remains seriously under-
resourced (41, 42). Nigeria, being the most 
populated country in West Africa has to take 
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the lead in tackling AMR using the ‘One 
Health’ approach, which acknowledges the 
links among humans, animals and the envi-
ronment as the corner stone of its plan (39). 
The government has focused on good leader-
ship, multidisciplinary approach, enforce-
ment of regulations, public education and 
community participation on tackling the 
growing AMR problem (39).  
The medical and veterinary health systems 
Health system consists of all organizations, 
people and actions whose primary intent is to 
promote, restore or maintain health (43). A 
good HS should be “STEEEP”, namely safe, 
timely, effective, efficient, equitable and pa-
tient-centred. The WHO Health System 
framework describes HS in terms of six core 
components or “building blocks”, which are 
leadership/governance, health workforce, fi-
nancing, service delivery, health information 
system and access to essential medicine, an-
tibiotics inclusive. Therefore, to preserve an-
tibiotic effectiveness, interventions need to 
be implemented throughout the whole HS 
and the whole of society (11). 
Universal Health Coverage 
Universal Health Coverage which is the ac-
cess by all who need all basic health care ser-
vices at a cost that will not expose them to 
financial hardship. It has the advantage of eq-
uity, quality, efficiency, accountability, sus-
tainability and resilience. UHC include finan-
cial risk protection, access to essential 
healthcare services, access to safe, effective, 
quality and affordable essential medicines 
and vaccines for all. The role of UHC is vital 
in order to have access to these essential med-
icines in Africa in particular, where majority 
of people pay for healthcare with out-of-
pocket expenditure (35, 36). It ensures access 
by all people, to all quality services at cost 
not exposing them into financial difficulties, 
and it is central to improved access to quality 
drugs e.g. antimicrobials. Financial access is 
crucial in view of the high poverty level and 
burden of infectious diseases in Africa (35). 
An estimated 11 million people become poor 
each year and one-third of Africans in need 
of healthcare do not have access because of 
financial barrier (36, 44). The UHC ensures 
that every citizen gets at least the minimum 
health package by the system. Health system 
could have structured financing mechanism 
in which the government pays for the people 
and the one in which the people contribute. 
However, a pooling financing mechanism 
(from government or insurance) could help in 
risk sharing and resources allocation for ma-
jority of the citizens. The National Health In-
surance Scheme (NHIS) is the best way to fi-
nance the HS whereby both government and 
individual have responsibilities for health and 
the mechanism gives people better access to 
healthcare. However, the NHIS in Nigeria 
mainly captures the formal sector (about 10% 
of the population) (45). Many countries in the 
region have 3 key financing sources namely, 
donor funding, OOP payment and tax-based 
government financing. OOP payments have 
increased in nearly all countries, and the re-
gional average has increased from US$15 per 
capita in 1995 to US$38 in 2014 (36), and 
OOP spending for health care services in Ni-
geria is among the highest in the world with 
72% [39]. This could lead to poor access to 
quality healthcare and quality antimicrobial 
which will result in AMR. Out-of-pocket 
payment is the simplest financing mecha-
nism, and because it does not ensure equity 
and financial risk protection, it is universally 
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agreed to be the worst way to finance HS 
(46). Here the health services are according 
to ability to pay not need. The UHC as an ap-
proach that is linked to financing mechanism, 
it has health, political and economic benefits 
(46), and can provide an ideal platform to 
manage AMR through adequate provision 
and rational use of antimicrobials (Table 1). 
The health system attributes and the UHC ac-
tions for addressing AMR include equity, 
quality, efficiency, accountability, sustaina-
bility and resilience. Universal Health Cover-
age can build system governance and coordi-
nation capacities that are highly relevant to 
tackling AMR (47). Government can take in-
formed decisions and wisely allocate health 
investment in areas such as training of health 
workers, strengthening of medical and veter-
inary systems, improved health information, 
effective infection prevention and control 
program, vaccines and evidence-based anti-
biotic stewardship program, research and de-
velopment (26, 33, 48). For the any UHC to 
be successful, the relevant stakeholders such 
as political leaders, community leaders, 
health professionals, academics, and research 
institutions, federal and state ministries of 
health, agriculture, and education and Non-
governmental organisations need to work to-
gether. 
Health Financing  
In the Abuja declaration of April 2001, the 
Heads of States of the AU countries pledged 
to set the target of at least 15% of the annual 
budgets to improve the health sector. How-
ever, only four countries met the Abuja target 
of 15 percent of general government spend-
ing in 2014. Limited commitment of domes-
tic resources is often reflected in shortages of 
critical inputs namely- manpower, materials, 
money and minute (4Ms). Financial protec-
tion is generally low in Africa, requiring most 
patients to pay for health services from their 
own household income (OOP payments). 
Out-of-pocket payment for health services 
predisposes person or families to catastrophic 
health expenditure and poverty. In addition, 
it does not allow pooling of resources and risk 
sharing that is beneficial to the sick persons 
and government. 
Access to essential medicines  
Sub-standard and counterfeit antibiotics are 
widely available in Africa and have a sub-
stantial negative impact on the medical and 
veterinary health systems. They facilitate 
AMR and worsen case-fatality. Patients with 
infectious diseases that are not properly 
treated could develop complications requir-
ing second-line medications that are very ex-
pensive; and sometimes may result in poor 
health outcomes. This can also happen in the 
veterinary hospitals/clinics. Nigeria is among 
the 10 countries projected to have increased 
antibiotics use in veterinary medicine by 
2030 (25).  
Leadership/governance  
Accelerating progress toward UHC in Africa 
is within reach but will require political lead-
ership and a clear strategic vision (36). The 
quality of leadership and stewardship varies 
at all levels of the health sector, from the top 
positions in the health down to officers’ in-
charge of hospitals or health centres. Laws 
and policies play critical roles in framing, en-
abling, and protecting public health. The AU 
and Africa CDC have been playing important 
role. Issues such as regulations for antimicro-
bials in food and feed, strengthening of anti- 
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Table 1: Entry-points for integrating AMR into Universal Health Covering using the 
Health Systems elements (Adapted from reference 43) 
  
Element of Health Systems Measures to tackle antimicrobial resistance 
Service delivery -Provision of clean water, sanitation, immunization, infection prevention and 
control 
-Facilitate rational drug use through diagnostics and primary health care 
- increase investment in veterinary services and animal health 
Health workforce -Invest in professional education, training, certification and development as 
well as regulation of professionals. 
- Joint scientific meetings and conferences by medical and veterinary profes-
sionals and other stakeholders 
Health information systems -Strengthen monitoring and surveillance across networks focusing on labora-
tories and set standards for diagnostics. 
Access to essential medicines -Ensure antimicrobials are accessible, but not used irrationally. This requires 
linking access with ensuring responsible use 
-Use alternatives to antibiotics such as probiotics, prebiotics, organic acids, 
exogenous enzymes and essential oils among others as growth promoters in 
animal production 
Health financing -Consider antimicrobial resistance a risk to both the sustainable financing of 
universal health coverage and the individual’s ability to pay for higher cost of 
treatment           
-Approach financing of universal health coverage through an antimicrobial 
resistance-lens  
-Delink health worker income and profit of companies and institutions from 
the volume of antimicrobials sold. 
Leadership/governance -Strong political leadership, advocacy and accountability 
-The impact of antimicrobial resistance goes beyond health care, and systems 
changes should therefore be applied to the agricultural and environmental 
sectors  
- Regulations on antimicrobial use and prevention of infections. 
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microbial policies, engaging civil society or-
ganisations and standard treatment guidelines 
for human, terrestrial and aquatic animals, 
plants and environment are very crucial 
(1,41). 
Health workforce  
Health professionals are the most critical in-
put in the delivery of health services and 
functioning of any HS. Sufficient human re-
sources with adequate education and skills 
are needed for AMR surveillance and control 
in both human and animal health sectors (1). 
Africa CDC has identified the need to pro-
mote stewardship programs to increase the 
proportions of physicians and veterinarians 
adhering to prudent antibiotic use guidelines, 
which will help delay emergence of AMR 
and improve outcomes among patients al-
ready infected with AMR organisms (1).  
Service delivery  
Health care services should be people-cen-
tred, qualitative, target the poor and margin-
alized, including those in hard-to-reach areas 
(35) which will improve access to basic ser-
vices to the majority. However, infrastructure 
in most government facilities in some Afri-
can countries is poor; hospital wards, outpa-
tient clinics, health centres and health posts, 
along with their water and electricity supplies 
and sanitation are usually in need of repair, 
renovation or expansion. Enhancing capacity 
of the health care workers will improve the 
quality of the health services, better health 
status of the people and animal and reduced 
incidence of sickness. 
Health information systems  
The critical need for timely, relevant and re-
liable medical and veterinary data to support 
evidence-based decision making is very im-
portant. Evidence based information is re-
quired to facilitate behavioural changes on 
appropriate use of antimicrobials and safe-
guard human and animal health (41). Health 
data is very essential for planning, delivery of 
evidence based health care services, research 
and tracking of HS (42). Real time and relia-
ble data will help in the planning of the med-
ical and veterinary services, identification of 
gaps and optimization of services. Updated 
antibiogram results will help in rational use 
of antibiotics and reduced misuse, which will 
decrease the emergence of AMR in medical 
and veterinary health sectors. 
The one health concept  
One Health is a collaborative effort of multi-
ple disciplines working locally, nationally, 
and globally to obtain optional health for peo-
ple, animals and our environment (47). One 
health is a public good that has the potential 
to mitigate the negative externality of AMR 
(47). The Canadian Science center for Hu-
man and Animal Health is the first organiza-
tion worldwide to house in one facility the la-
boratory for human and animal diseases re-
search (47). Studies have shown that imple-
menting one health especially in low income 
countries will save lots of money for the vet-
erinary and medical health systems (49). This 
money can be used to enhance surveillance 
and improve capacities in medical and veter-
inary HS. Surveillance systems are the foun-
dation for a better understanding of the epi-
demiology of AMR and the key for tackling 




Joshua IA, Bauche J, Abdulla S. Managing Antimicrobial Resistance from Medical and Veterinary 
Health Systems Perspectives to Achieving Universal Health Coverage in the African Region (Review 
Article). SEEJPH 2021, posted: 18 May 2021. DOI: 10.11576/seejph-4446 
 
11 | P a g e  
 
Conclusion 
Universal Health Coverage is an important 
approach to combat AMR through medical 
and veterinary HS strengthening as AMR is a 
threat to social, economic, health and devel-
opment. Also tackling AMR will require rel-
evant stakeholders and concerted, multi-sec-
toral and multi-disciplinary approach at 
global, regional, national and local levels that 
is sustainable. 
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